Business
Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors
MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,
About this update from Tenax Therapeutics, Inc.
[{"type":"text","content":"MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that Tenax Therapeutics appointed Robyn Hunter to its Board of Directors, effective January 28, 2022. Ms. Hunter is an independent director and will chair the Board’s audit and compliance committee. “We are very pleased to welcome Robyn to our Board of Directors,” said Christopher T. Giordano, President and Chief Executive Officer of Tenax Therapeutics. “Robyn brings a wealth of financial and operational expertise within the life sciences industry to our Board. She has significant experience in development-stage biotechnology companies, and I expect will provide Tenax an invaluable industry perspective as we advance our two lead drug candidates, TNX-201 and TNX-102, into pivotal testing.” Ms. Hunter currently serves as the Chief Financial Officer of Fortress Biotech, Inc., an innovative biopharmaceutical company. From August 2011 to June 2017, Ms. Hunter served as the Vice President and Corporate Controller of Fortress Biotech. Prior to joining Fortress Biotech, she served as Senior Vice President and Chief Financial Officer of Schochet Associates, Inc. from January 2006 to May 2011. From August 2004 to January 2006, Ms. Hunter served as the Corporate Controller for Indevus Pharmaceuticals, Inc. Earlier in her career, Ms. Hunter held several positions from Accounting Manager to Vice President and Treasurer of The Stackpole Corporation. Ms. Hunter holds a B.A. in Economics from Union College in Schenectady, New York. “I look forward to joining Tenax’s Board of Directors, particularly at this stage of the Company’s growth. Tenax is positioned to advance two drugs into Phase 3 testing in the coming months, with each drug having the potential to address a significant unmet medical need in cardiovascular medicine. With imatinib and levosimendan having already demonstrated proof-of-concept in the clinic, I believe Tenax represents a unique opportunity to bring significant value to both patients and its shareholders, and I am very happy to help guide the Company as it advances these two programs.” About Tenax Therapeutics Tenax Therapeutics, Inc. is ...